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The aim of the present study was to investigate the tissue distribution and excretion of five components of 
Portulaca oleracea L. extract (POE) in rat following oral administration. A rapid, sensitive and specific 
ultra-high performance liquid chromatography (UHPLC) method with puerarin as the internal standard 
was used for the quantitative analysis of five components of POE, including caffeic acid (CA), p-coumaric 
acid (p-CA), ferulic acid (FA), quercitrin (QUER) and hesperidin (HP) in rat tissues including the liver, 
intestine, stomach, muscle, heart, lung, brain, kidney and spleen, urine and feces. The results show that 
only p-CA and FA were found in nearly all tissues with low cumulative ratios, and CA was higher in the 
intestine and stomach with a slightly higher cumulative ratio in the urine and feces after 24 h. HP and 
QUER were found at low levels in the tissues with low cumulative ratios.
Uniterms: Portulaca oleracea L./pharmacokinetics. Portulaca oleracea L./extract/experimental study. 
Portulaca oleracea L./extract/ tissue distribution. Portulaca oleracea L./extrato/excretion. Compostos 
fenólicos. Ultra performance liquid chromatography/quantitative analysis.
O objetivo do presente estudo foi investigar a distribuição tecidual e excreção de cinco componentes 
de extrato Portulaca oleracea L. (POE) em ratos após administração oral. Um método analítico rápido, 
sensível e específico para quantificação de cinco componentes de POE (ácido cafeico (CA), ácido 
p-cumárico (p-CA), ácido ferúlico (FA), quercitrina (QUER) e hesperidina (HP)) por cromatografia líquida 
de ultra eficiência (UHPLC), empregando puerarina como padrão interno de referência. Os compostos 
foram quantificados em diferentes tecidos dos animais, sendo eles fígado, intestino, estômago, músculo, 
coração, pulmão, cérebro, rim e baço, urina e fezes. Os resultados mostraram que apenas p-CA e FA 
foram encontradas em todos os tecidos com baixas taxas cumulativas e CA apresentou níveis mais altos 
no intestino e estômago com a taxa cumulativa um pouco mais elevada na urina e nas fezes após 24 h. 
HP e QUER apresentaram baixas concentrações nos tecidos com baixas taxas cumulativas.
Uniterms: Portulaca oleracea L./farmacocinética. Portulaca oleracea L./extrato/estudo experimental. 
Portulaca oleracea L./extrato/distribuição tecidual. Portulaca oleracea L./extrato/excreção. Compostos 
fenólicos. Cromatografia líquida de ultra eficiência/análise quantitativa.
INTRODUCTION
Portulaca oleracea L. is a well-known traditional 
Chinese medicine and is recorded in the Chinese 
pharmacopoeia (PRC, 2010). It has historically been used 
for removing heat, counteracting toxicity, cooling the 
blood, hemostasis and treating dysentery. As P. oleracea 
L. is also a widespread and abundant plant in the world, 
much attention has been paid to its pharmacological study, 
such as its anti-inflammatory and anti-pruritic (Lim et 
al., 2011), hypocholesterolemic (Movahedian, Ghannadi, 
Vashimia, 2007) and hypoglycemic (Gong et al., 2009) 
effects. Some reports have focused on in vitro and in 
vivo analyses of the components in P. oleracea L. extract 
(POE) i.e., flavonoids, by capillary electrophoresis with 
electrochemical detection (Xu, Yu, Chen, 2006), and four 
compounds of POE have been detected in rat plasma by 
HPLC after intravenous administration of P. oleracea 
L. (Cheng et al., 2012). However, there is little known 
regarding the tissue distribution and excretion of POE. 
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Therefore, a rapid, sensitive and specific UHPLC method 
with an internal standard was established to evaluate the 
tissue distribution and excretion of five components of 
Portulaca oleracea L. extract (POE), including caffeic 
acid (CA), p-coumaric acid (p-CA), ferulic acid (FA), 
quercitrin (QUER) and hesperidin (HP), after oral 
administration in rats, which will fill in some of the gaps 
in our overall knowledge of POE.
MATERIAL AND METHODS
Plant material
Portulaca oleracea L. was collected from the 
collection site with the geographical coordinates 37°27′-
38°47′ N, 113°30′-115°20′ E (Anguo, Hebei, China) in 
September 2013, and identified by Prof. Yanjun Zhai. A 
voucher specimen (No. 20130925) was deposited at the 
School of Pharmacy, Liaoning University of Traditional 
Chinese Medicine.
Reagents and chemicals
Puerarin as the internal standard (IS) and QUER 
were purchased from the National Institute for the Control 
of Pharmaceutical and Biological Products (Beijing, 
China), and CA, p-CA, FA and HP were obtained from 
Sichuan Weikeqi Biological Technology Co., Ltd 
(Chengdu, China). Figure 1 illustrates the chemical 
structures of the five investigated components and the IS. 
Methanol and acetonitrile were of HPLC grade provided 
by Damao Chemical Reagent Plant (Tianjin, China). 
Purified water was obtained from Wahaha Group Ltd., Co. 
(Shenyang, China). All other reagents were of analytical 
grade purchased from Jinfeng Chemical Factory (Tianjin, 
China).
Chromatographic system and conditions
The analysis was performed on a NEXERA X2 
UHPLC LC-30A system (Japan, Shimadzu) was 
equipped with a solvent delivery pump (LC-30AD), 
a vacuum degasser (DGU-20A), a Shimadzu UV-is 
spectrophotometric detector (SPD-20A) and LabStation 
software (Shimadzu). The analytes were determined on an 
analytical shim-pack ODS column (75mm × 2 mm, 1.6 µm 
particle size, Shimadzu, Japan) at a column temperature 
of 40ºC incorporating a UV detector at a flow rate of 0.3 
mL/min with the detection wavelength set at 320 nm. 
The mobile phase consisted of phase A (acetonitrile) and 
B (0.1% acetic acid aqueous) in a gradient elution: 8% 
A within 0-2 min, 16% A within 2-4 min, 17% A within 
4-6 min, 25% A within 6-7 min, 45% A within 7-10 min 
and then returned to initial condition for a 10 min re-
equilibration, with a total run time of 20 min. The mobile 
phase was passed under vacuum through a 0.22 μm filter 
membrane and degassed by exposure to ultrasonic waves 
before use.
Animals
Male Wistar rats (body weight 300 ± 20 g) were 
provided by the Laboratory Animal Center of Dalian 
University (Dalian China). All rats were kept in a 
controlled environment for a week and had free access 
to standard laboratory food and water intake before the 
experiments. The rats were fasted overnight prior to 
the administration of POE. Animal experiments were 
carried out in accordance with the Guidelines for Animal 
Experimentation of Liaoning University of Traditional 
Chinese Medicine, and the procedure was approved by the 
Animal Ethics Committee of this institution (20140528).
Preparation of the POE solution
Whole dried P. oleracea L. (3 kg) was refluxed twice 
with water (30 L), each for 1 h, then POE was obtained 
after the water was removed under reduced pressure. Then, 
the residue was passed through an AB-8 macroporous 
resin column (8 × 100 cm, Shanghai, China). To eliminate 
impurities, the column was eluted with 15 L of water 
and eluted with 30 L of 50% ethanol. After removing 
the ethanol of the 50% ethanol fraction in vacuo, the 
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FIGURE 1 - Chemical structures of the five analytes and internal 
standard.
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suspended solution of POE was obtained and stored at 
4 °C prior to use. Using the external standard method for 
quantification, the contents of CA, p-CA, FA, QUER and 
HP in the suspended solution of extract were found to be 
0.467, 0.146, 0.433, 0.0738 and 1.60 mg/mL, respectively.
Preparation of standards and quality control 
samples
The stock solutions of the five standard compounds 
CA, p-CA, FA, QUER, HP and the IS were precisely 
weighed and dissolved using ultrasound in methanol, 
to yield concentrations of 235, 221, 327, 259, 242 and 
212 ug·mL-1, respectively.
For the tissue assay, five calibrators of CA (0.05, 
0.1, 0.2, 0.5, 1.25 and 5.0 ug·mL-1), p-CA (0.05, 0.1, 0.2, 
0.5, 1.25 and 5.0 ug·mL-1), FA (0.1, 0.2, 0.4, 1.0, 2.5 and 
10.0 ug·mL-1), QUER (0.075, 0.15, 0.3, 0.75, 1.875 and 
7.5 ug·mL-1) and HP (0.4, 0.8, 1.6, 4, 10 and 40 ug·mL-1) 
were prepared by adding standard working solutions 
(50 μL) and the IS (10 μL) to drug-free rat tissues. All 
stock and working standard solutions were stored in 
brown bottles at 4ºC until analysis. Quality control (QC) 
tissue samples were prepared at low, medium and high 
concentrations (0.125, 0.7 and 4 ug·mL-1 for CA and p-CA; 
0.25, 1.4 and 7.98 ug·mL-1 for FA; 0.1875, 1.05 and 5.985 
ug·mL-1 for QUER; 1.0, 5.7 and 32 ug·mL-1 for HP) in bulk 
and aliquots were stored at -20 °C until analysis.
For the urine and feces assay, five calibrators of CA 
(0.15, 0.3, 0.6, 1.5, 3.75 and 15 ug·mL-1), p-CA (0.125, 
0.25, 0.5, 1, 2.5 and 6.25 ug·mL-1), FA(0.09, 0.18, 0.35, 
0.88, 2.19 and 5.47 ug·mL-1), QUER (0.19, 0.38, 0.75, 
1.88, 4.69 and 18.75 ug·mL-1), and HP (1.25, 2.5, 5, 10, 
25 and 75 ug·mL-1) were prepared by adding standard 
working solutions (50 μL) and IS (50 μL) to drug-free 
rat urine/fecal samples. All stock and working standard 
solutions were stored in brown bottles at 4ºC until 
analysis. The quality control (QC) samples of urine/feces 
were prepared at low, medium and high concentrations 
(0.38, 4.25 and 48.00 ug·mL-1 for CA; 0.63, 7.07 and 
80.00 ug·mL-1 for p-CA; 0.22, 3.91 and70.00 ug·mL-1 for 
FA; 0.1875, 0.47, 5.30 and 60.00 ug·mL-1 for QUER; 3.13, 
13.69 and 60.00 ug·mL-1 for HP) in bulk and aliquots were 
stored at -20 °C until analysis.
Preparation of biosamples
Twenty-five rats were divided into five groups 
(n = 5) at random. All rats were orally dosed with POE 
at a dose of 8.4 mL·kg-1, (approximately equivalent to 
3.92 mg·kg-1 of CA, 1.23 mg·kg-1 of p-CA, 3.64 mg·kg-1 
of FA, 0.62 mg·kg-1 of QUER and 13.47 mg·kg-1 of HP). 
Also, tens rat were divided into two groups (n=5) at 
random for the urine and feces assay.
For the tissue assay, the dosed rats were sacrificed 
and tissues removed at 10, 30, 60, 90 and 150 min. Tissues 
were collected, including liver, intestine, stomach, muscle, 
heart, lung, brain, kidney and spleen. All tissues were 
rinsed with physiological saline, blotted on filter paper 
and weighed (the contents of stomach and intestine were 
removed before rinsing). Approximately 0.2 g of each 
tissue was weighed out and homogenized in 0.5 mL of 
saline solution, then centrifuged at 3000 rpm for 15 min. 
Tissue samples were stored at -20 °C until analysis.
The homogenized tissue samples (0.2 mL) were 
supplemented with 10 μL of the IS, 20 μL of acetic acid 
and 1 mL of methanol, followed by vortex mixing for 
1 min, then centrifuged at 3000 rpm for 15 min. The 
supernatant was collected and evaporated to dryness at 
50 °C under a gentle stream of nitrogen. Then, the dried 
residue was reconstituted in 100 μL of the initial mobile 
phase and centrifuged at 10,000 rpm for 10 min. A 1 μL 
aliquot of the supernatant was injected into the UHPLC 
system for analysis.
For the urine and feces assay, all the rats were housed 
in stainless-steel metabolism cages to collect urine and 
feces at 0-2 h, 2-4 h, 4-8 h, 8-12 h and 12-24 h post-dosing. 
Water and standard laboratory food were offered during 
the whole experiment. The volume of the each collected 
urine sample and the weight of each collected feces sample 
were respectively recorded. All the samples were stored 
at –20°C until analysis.
Urine samples (200 μL) were supplemented with 
50 μL of the IS, 20 μL of acetic acid and 1 mL of methanol 
and pipetted, followed by vortex mixing for 1 min. After 
centrifugation at 3000 rpm for 15 min, the supernatant was 
separated and evaporated to dryness under a gentle stream 
of nitrogen at 40°C. The residue was reconstituted in 
200 μL of the mobile phase and centrifuged at 10,000 rpm 
for 10 min. Then, a 1 μL aliquot of the clean supernatant 
was injected into the UHPLC system for analysis.
About 0.2 g of feces was homogenized in 0.5 mL of 
physiological saline solution (w/v, 2/5). The homogenate 
was then supplemented with 50 μL of the IS, 20 μL of 
acetic acid and 1 mL of methanol, then treated further in 
a similar manner as the urine samples.
Method validation
Selectivity
The selectivity was determined by comparing 
chromatograms of mixed blank tissues/urine/feces obtained 
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from five drug-free rats with those of corresponding 
standard tissue/urine/feces samples spiked with the five 
standard solutions and IS, as well as the biosamples 
obtained after oral administration of POE. 
Linearity, LOD and LLOQ
The calibration curves of tissues were performed 
over the linear range of 0.05-5 ug·mL-1 CA, 0.05-5 ug·mL-1 
p-CA, 0.1-10 ug·mL-1 FA, 0.075-7.5 ug·mL-1 QUER, and 
0.4-40 ug·mL-1 HP. The calibration curves of urine/feces 
were performed over the linear range of 0.15-60 ug·mL-1 
CA, 0.125-100 ug·mL-1 p-CA, 0.0875-87.5 ug·mL-1 
FA, 0.1875-75 ug·mL-1 QUER, and 1.25-75 ug·mL-1 
HP). The calibration curves for each analyte in different 
tissue/urine/fecal samples were generated by plotting the 
area ratio of five compounds to the IS separately vs. the 
nominal concentration in the standard tissue/urine/fecal 
samples. Moreover, the weighted (1/c2) least-square linear 
regression was applied to obtain the regression equation. 
The LOD (limit of detection) was determined by diluting 
the QC samples stepwise, given as the signal-to-noise 
ratio (S/N = 3). The lower limit of quantification (LLOQ), 
considered to be the lowest concentration point in the 
calibration curves, displayed an acceptable accuracy (RE) 
within ± 15% and a precision of less than 20%.
Precision and accuracy
Five replicates of QC tissue/urine/fecal samples at 
three concentrations were assessed to calculate the intra-
day precision and accuracy on the same day. Inter-day 
precision was determined by analyzing the QC tissue/
urine/feces samples over three consecutive days. The 
intra-day and inter-day precision were defined as the 
relative standard deviation, and accuracy was determined 
by calculating the relative error (RE). 
Extraction recovery
The extraction recoveries of five compounds were 
determined by comparing the peak area of each compound 
from QC samples at three concentrations with that of the 
unextracted standard solutions containing the equivalent 
amount of analytes regarded as 100% recovery. 
Stability
The stability of QC samples was investigated at three 
concentrations, i.e. low, medium and high. The short-term 
stability experiment was conducted at ambient temperature 
(25 °C) for 24 h, and long-term stability was assessed after 
storage at -20 °C for 1 month. The freeze (-20 °C)-thaw 
(room temperature) stability was assessed after three 
freeze-thaw cycles.
RESULTS AND DISCUSSION 
Method development and optimization
In order to obtain suitable retention times and 
good separation for the five components in the POE 
and IS, different combinations of several mobile phases 
were chosen, i.e. methanol-water and acetonitrile-water. 
Comparatively, there existed a serious baseline drift and 
interference of endogenous components in the tissues 
with analytes using the methanol-water system; besides, 
we could not obtain satisfactory separation among the 
compounds in POE. These problems were ultimately 
solved by using acetonitrile-water as the mobile phase in 
gradient elution, into which some acetic acid was added 
in order to obtain perfect peak shapes.
Three different wavelengths (270, 320 and 360 
nm) were chosen to achieve high sensitivity for the five 
investigated components of POE. Finally, a detection 
wavelength of 320 nm was applied for the simultaneous 
analysis of the five compounds with no interference.
Method validation
Selectivity
To determine the selectivity of this method, blank 
tissues/urine/feces, tissues/urine/feces spiked with known 
amounts of the five reference substances, and tissue/urine/
feces removed from rats after oral dosing with POE were 
analyzed. The chromatograms of the stomach were chosen 
as an example (Figure 2) and show that there were no 
interfering peaks in the region of the peaks of the analytes. 
The retention times of CA, IS, p-CA, FA, QUER, and HP 
were approximately at 3.61, 4.42, 5.24, 6.25, 7.11 and 8.21 
min, respectively. The total run time was 10 min. 
Linearity, LOD and LLOQ 
The calibration curves, correlation coefficients and 
linear ranges of the five compounds in each tissue are 
given in Table I. The LODs of the five components, i.e. 
CA, p-CA, FA, QUER and HP were 0.015, 0.015, 0.03, 
0.0225 and 0.12 ug·mL-1, respectively. The LLOQ of the 
five components was defined as the lowest concentration 
on the calibration curve with precision/accuracy within 
20%, verified by repeated analysis. The calibration 
curves, correlation coefficients and linear ranges of the 
five compounds in urine/feces are given in Table II. The 
LODs of the five components, i.e. CA, p-CA, FA, QUER 
and HP were 0.045, 0.0375, 0.026, 0.056 and 0.375 
ug·mL-1, respectively. The LLOQ of the five components 
was defined as the lowest concentration on the calibration 
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curve with precision/accuracy within 20%, verified by 
repeated analysis.
Precision and accuracy 
The intra- and inter-day precision/accuracy of each 
analyte in the tissue QC samples at three concentrations 
are given in Table III. The intra- and inter-day precision/
accuracy of each analyte in the urine/feces QC samples at 
three concentrations are given in Tables IV/V. The RSDs 
of the five compounds were all < 20% for the intra-day and 
inter-day assays, which is in accordance with the guidance 
of the USFDA (FDA, 2001).
Extraction recovery and stability
Tables III-V show that the extraction recoveries of 
the five compounds in different tissues ranged from 82.14 
± 1.03% to 93.62 ± 2.71%, and that of the IS was 92.93 ± 
3.14%, 81.64 ± 2.48% to 94.93 ± 2.34% in the urine and 
83.36 ± 0.35% to 93.65 ± 2.41% in the feces, demonstrating 
that there was negligible loss during extraction, which 
could be attributed to the high solubility of the analytes 
in methanol and the one-step protein precipitation used 
in the sample preparation. The results of the short-term 
stability, long-term stability and freeze-thaw stability 
also indicated that no remarkable degradation occurred 
during the chromatography, extraction and sample storage 
processes for excreta samples. 
Tissue distribution assay
The concentrations of the five components in the 
nine tissues collected at 10, 30, 60, 90 and 150 min after 
oral administration of POE are shown in Table VI. 
Although the chemical structures of CA, p-CA and 
FA were similar, their concentrations in the tissues were 
significantly different (Table VI). After oral administration 
of the POE in rats, only p-CA and FA were found in all 
tissues (except for p-CA in the brain). The reason why 
p-CA was higher in tissues (except for the brain) is that the 
transepithelial transport of p-CA depends on concentration 
and saturation (Konishi, Kobayashi, Shimizu, 2003), and 
higher FA levels in the intestine could partly be attributed 
to gradual efflux from the stomach. CA was only observed 
in the stomach and intestine at the different five points, and 
in the muscle at the first point. Both QUER and HP are 
flavonoids, and their behaviors were basically consistent 
in vivo after gavage (Table VI). QUER was abundant in 
the stomach and intestine but only a little was found in 
the liver, and the highest concentrations of HP were in the 
stomach with low levels in the liver, kidney and intestine; 
HP was not found in other tissues. Bacteria and/or enzyme-
related hydrolysis of HP in the gastrointestinal tract is an 
important factor responsible for the poor absorption of 
HP, and its absorption might depend on the type of sugar 
moiety bonded to the aglycone (Chang et al., 2005). 
Excretion assay
The cumulative ratios of the five analytes are 
FIGURE 2 - Typical chromatograms A-C. Blank stomach sample 
A, blank stomach sample spiked with standard five compounds 
and IS B, and stomach sample after oral administration of POE 
at 90min C. (peak 1 CA; peak 2 IS.; peak 3 p-CA; peak 4 FA; 
peak 5 QUER; peak 6 HP).
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TABLE II - Calibration curves, correlation coefficients and linear ranges of the five compounds in the urine/feces samples
Biosamples Calibration curves r2 Linear ranges (mg·mL-1)
CA Urine y = 0.4509 x – 0.0432 0.996 0.15–60
Feces y = 0.9042 x – 0.128 0.991
p-CA Urine y = 0.6069 x + 0.043 0.992 0.125–100
Feces y = 2.2008 x – 0.2654 0.992
FA Urine y = 0.1407 x + 0.1069 0.996 0.0875–87.5
Feces y = 0.2456 x + 0.047 0.996
QUER Urine y = 0.0345 x + 0.0258 0.998 0.1875–75
Feces y = 0.0175 x + 0.0526 0.994
HP Urine y = 0.4509 x – 0.0432 0.992 1.25–75
Feces y = 0.9042 x – 0.128 0.996
y, peak area ratio; x, concentration of the reference standard (mg·mL-1); r, correlation coefficient.
TABLE I - Calibration curves, correlation coefficients and linear ranges of the five compounds in the tissue samples
Biosamples Calibration curves r2
Linear range 
(mg·mL-1)
Biosamples Calibration curves r2
Linear range 
(mg·mL-1)
CA
stomach y=4.7598x+0.3953 0.999
0.05-5 FA
stomach y=3.9862x+0.6429 0.9998
0.1-10
liver y=5.1869x+0.1426 0.9932 liver y=3.2723x+0.2441 0.999
intestine y=6.5169x+0.0752 0.9994 intestine y=3.7437x+0.3976 0.999
muscle y=3.6674x+0.0644 0.9994 muscle y=3.2464x+0.1811 0.9992
heart y=2.1671x+0.1147 0.9968 heart y=2.6317x+0.0206 0.999
lung y=4.32751x+0.2351 0.991 lung y=3.0402x+0.2042 0.999
brain y=4.6791x+0.673 0.994 brain y=2.8763x+0.4505 0.9996
kidney y=4.1844x+0.4002 0.9902 kidney y=0.5426x+0.2368 0.9934
spleen y=1.2381x+0.1635 0.993 spleen y=3.1617x+0.0763 0.9948
p-CA
stomach y=8.9653x+0.5561 0.9992
0.05-5 QUER
stomach y=1.9548x+0.2086 0.9998
0.075-7.5
liver y=7.8747x+0.2996 0.999 liver y=1.4638x+0.1653 0.999
intestine y=8.6427x+0.3888 0.999 intestine y=1.7038x+0.1838 0.9992
muscle y=8.7493x+0.2771 0.9994 muscle y=1.2381x+0.0074 0.999
heart y=7.4364x+0.1338 0.9992 heart y=0.6773x+0.1474 0.997
lung y=7.3137x+0.2229 0.999 lung y=0.937x+0.1624 0.9986
brain y=6.4779x+0.5136 0.999 brain y=1.0706x+0.3502 0.997
kidney y=7.3448x+0.7083 0.9924 kidney y=0.6990x+0.1709 0.996
spleen y=6.9256x+0.2891 0.9924 spleen y=1.134x+0.1163 0.991
HP
stomach y=0.1299x+0.0483 0.9994
0.4-40
liver y=0.1252x+0.0459 0.9994
intestine y=0.1184x+0.0204 0.9994
muscle y=0.1178x+0.0526 0.9996
heart y=0.1156x+0.0946 0.9994
lung y=0.1110x+0.1166 0.994
brain y=0.0884x+0.1894 0.9936
kidney y=0.1004x+0.1126 0,997
spleen y=0.0952x+0.1656 0.998
y, peak area ratio; x, concentration of the reference standard (mg·mL-1); r, correlation coefficient.
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TABLE III - Extraction recovery, precision, accuracy and stability of the five compounds in stomach. (n = 5)
Added conc. 
(mg·mL-1)
Extraction 
recovery 
Intra-day Inter-day Accuracy (%, mean ± SD)
Found conc. 
(mg·mL-1)
RSD 
(%)
RE 
(%)
Found conc. 
(mg·mL-1)
RSD 
(%)
RE 
(%)
Short-term 
stability
Long-term 
stability
Freeze-thaw 
stability
0.125 84.41 ± 0.92 0.12 ± 0.01 6.40 -3.3 0.12 ± 0.01 5.07 -3.2 90.90 ± 0.95 88.41 ± 0.92 94.25 ± 2.07
CA 0.7 86.96 ± 2.22 0.66 ± 0.01 1.67 -6.2 0.67 ± 0.03 4.70 -6.4 86.48 ± 4.88 86.96 ± 2.22 86.12 ± 2.46
4 91.03 ± 1.74 3.76 ± 0.10 2.53 -5.9 3.69 ± 0.12 3.12 -7.7 92.51 ± 3.50 94.03 ± 4.88 91.67 ± 5.10
0.125 85.36 ± 0.55 0.12 ± 0.03 1.66 -3.1 0.12 ± 0.01 5.92 -3.9 91.97 ± 1.57 85.36 ± 0.55 85.98 ± 1.17
p-CA 0.7 87.48 ± 3.09 0.67 ± 0.03 4.04 -4.7 0.66 ± 0.01 0.83 -6.2 86.56 ± 4.08 87.48 ± 3.09 88.62 ± 0.49
4 90.35 ± 1.13 3.73 ± 0.07 1.94 -6.8 3.72 ± 0.03 0.78 -7.0 85.06 ± 5.11 90.35 ± 4.13 93.48 ± 4.94
0.125 82.14 ± 1.03 0.13 ± 0.01 4.10 3.2 0.13 ± 0.02 2.16 0.3 92.54 ± 0.90 97.14 ± 3.03 102.5 ± 4.06
FA 0.7 86.52 ± 3.07 0.72 ± 0.05 7.11 2.8 0.75 ± 0.01 1.86 6.6 108.0 ± 2.85 106.5 ± 3.07 93.24 ± 0.31
4 83.64 ± 2.78 4.20 ± 0.14 3.38 4.9 4.23 ± 0.09 2.18 5.8 103.3 ± 0.07 100.6 ± 2.78 105.3 ± 5.75
0.188 84.39 ± 2.08 0.18 ± 0.01 6.70 -2.5 0.179 ± 0.01 7.10 -5.0 97.29 ±1.81 99.39 ± 2.08 87.29 ± 2.78
QUER 1.05 93.04 ± 3.45 1.01 ± 0.02 1.79 -3.8 1.01 ± 0.10 9.91 -4.0 88.40 ± 5.83 93.04 ± 3.45 88.93 ± 4.41
6 87.01 ± 4.80 5.62 ± 0.15 2.74 -6.4 5.98 ± 0.16 2.65 -0.4 109.6 ± 1.35 87.01 ± 4.80 92.36 ± 5.47
4 82.55 ± 1.55 3.78 ± 0.10 2.65 -5.51 3.81 ± 0.17 4.53 -4.79 89.64 ± 3.77 91.55 ± 1.55 88.98 ± 3.68
HP 22.4 93.62 ± 2.71 23.17 ± 1.65 7.11 3.45 23.72 ± 1.16 4.88 5.90 103.9 ± 3.53 99.62 ± 2.71 94.46 ± 4.85
127.68 86.40 ± 3.60 118.9 ± 1.04 0.87 -6.92 119.2 ± 2.11 1.77 -6.67 87.10 ± 3.73 86.40 ± 4.60 89.85 ± 4.15
TABLE IV - Extraction recovery, precision, accuracy and stability of the five compounds in urine. (n = 5)
Added conc. 
(mg·mL-1)
Extraction 
recovery 
Intra-day Inter-day Accuracy (%, mean ± SD)
Found conc. 
(mg·mL-1)
RSD 
(%)
RE 
(%)
Found conc. 
(mg·mL-1)
RSD 
(%)
RE 
(%)
Short-term 
stability
Long-term 
stability
Freeze-thaw 
stability
CA
0.375 86.41 ± 0.42 0.37 ± 0.01 0.60 -1.1 0.38 ± 0.01 0.72 0.3 100.9 ± 0.01 100.8 ± 0.02 98.78 ± 0.03
4.25 85.66 ± 1.22 4.30 ± 0.02 0.42 1.1 4.43 ± 0.21 4.75 4.2 104.3 ± 0.06 102.8 ± 0.17 100.8 ± 0.04
48 91.43 ± 1.54 49.12 ± 1.05 2.14 2.3 49.30 ± 0.36 0.74 2.7 103.9 ± 0.93 101.1 ± 1.10 110.1 ± 1.20
P-CA
0.625 88.36 ± 0.95 0.64 ± 0.02 3.15 2.4 0.65 ± 0.03 5.01 4.7 105.7 ± 0.04 105.5 ± 0.03 102.3 ± 0.02
7.07 89.48 ± 2.09 7.39 ± 0.07 0.91 4.6 7.62 ± 0.28 3.74 7.8 107.9 ± 0.02 106.4 ± 0.22 104.3 ± 0.04
80 92.35 ± 1.33 86.43 ± 1.82 2.11 8.0 82.73 ± 0.59 0.71 3.4 109.7 ± 1.60 106.7 ± 1.98 106.3 ± 2.16
FA
0.22 87.14 ± 1.53 0.22 ± 0.01 2.72 0.6 0.23 ± 0.01 2.55 2.9 103.9 ± 0.02 103.8 ± 0.01 100.4 ± 0.01
3.91 88.52 ± 2.07 3.76 ± 0.02 0.50 -3.8 3.88 ± 0.19 4.77 -0.8 99.31 ± 0.05 97.90 ± 0.15 95.99 ± 0.03
70.00 81.64 ± 2.48 72.56 ± 1.6 2.20 3.7 65.82 ± 0.61 0.92 -6.0 105.3 ± 1.27 102.4 ± 1.89 101.3 ± 1.62
QUER
0.47 82.39 ± 1.08 0.48 ± 0.04 8.26 1.6 0.50 ± 0.02 3.65 6.7 108.9 ± 0.04 108. 7 ± 0.03 101.3 ± 0.04
5.30 93.04 ± 3.45 5.28 ± 0.08 1.46 -0.5 4.94 ± 0.30 6.14 -6.8 103.2 ± 0.12 101. 6 ± 0.28 99.30 ± 0.10
60.00 89.01 ± 2.80 55.59 ± 1.88 3.39 -7.4 65.40 ± 0.50 0.76 9.0 94.16 ± 2.41 91.59 ± 3.24 99.96 ± 3.75
HP
3.13 85.55 ± 1.45 3.28 ± 0.12 3.53 4.8 3.35 ± 0.11 3.34 7.3 108.5 ± 0.19 108.3 ± 0.08 104.7 ± 0.1
13.69 93.62 ± 2.71 14.16 ± 0.13 0.92 3.5 14.63 ± 0.69 4.71 6.8 106.9 ± 0.16 105.4 ± 0.56 103.2 ± 0.14
60.00 84.40 ± 3.60 61.14 ± 1.30 2.12 1.9 59.94 ± 0.37 0.61 -0.1 103.5 ± 1.22 100.6 ± 1.32 109.9 ± 1.48
listed in Figure 3. Six hours after delivery, CA and FA 
all reached maximum excretion in the urine and feces, 
and were eliminated slowly after that. The cumulative 
ratios after 24 h were above 90% in the total excreta, 
indicating that they were completely eliminated within 
24 h after oral administration. In the combined results 
of the tissue distributions analysis, p-CA was abundant 
in all tissues except for brain, but the low cumulative 
ratio of p-CA, i.e. 3.70 ± 0.25% after 24 h (3.36 ± 0.24% 
in the urinary excretion and 0.04 ± 0.01% in the fecal 
excretion) indicated that p-CA was directly absorbed 
into the bloodstream. QUER and HP also presented low 
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TABLE V - Extraction recovery, precision, accuracy and stability of the five compounds in feces. (n = 5)
Added conc. 
(mg·mL-1)
Extraction 
recovery 
Intra-day Inter-day Accuracy (%, mean ± SD)
Found conc. 
(mg·mL-1)
RSD 
(%)
RE 
(%)
Found conc. 
(mg·mL-1)
RSD 
(%)
RE 
(%)
Short-term 
stability
Long-term 
stability
Freeze-thaw 
stability
CA
0.375 87.41 ± 0.72 0.36 ± 0.02 4.97 -2.8 0.37 ± 0.02 4.86 -0.8 99.25 ± 0.02 97.30 ± 0.02 98.67 ± 0.02
4.25 89.96 ± 2.52 3.85 ± 0.05 1.35 -9.5 3.89 ± 0.13 3.35 -8.4 92.25 ± 0.17 90.68 ± 0.04 93.46 ± 0.20
48 91.43 ± 1.44 48.70 ± 0.90 1.84 1.5 44.69 ± 0.74 1.65 -6.9 93.11 ± 0.74 94.29 ± 1.15 85.54 ± 0.46
P-CA
0.625 83.36 ± 0.35 0.64 ± 0.02 2.37 1.7 0.66 ± 0.02 3.57 4.9 104.9 ± 0.02 101.8 ± 0.02 104.5 ± 0.03
7.07 88.48 ± 2.89 7.18 ± 0.11 1.59 1.6 7.32 ± 0.34 4.62 3.6 103.6 ± 0.34 101.8 ± 0.08 105.1 ± 0.41
80 91.35 ± 1.33 83.33 ± 2.46 2.95 4.2 76.45 ± 2.22 2.90 -4.4 95.57 ± 2.22 96.73 ± 1.1 87.75 ± 1.03
FA
0.22 85.14 ± 1.23 0.22 ± 0.01 4.46 1.8 0.23 ± 0.01 2.26 5.2 105.2 ± 0.01 101.9 ± 0.01 99.27± 0.01
3.91 89.52 ± 3.17 4.15 ± 0.04 1.07 6.1 4.23 ± 0.15 3.66 8.2 104.3 ± 0.18 106.3 ± 0.04 104.4 ± 0.23
70.00 88.64 ± 2.38 69.51 ± 2.32 3.34 -0.7 63.78 ± 1.78 2.78 -8.9 97.48 ± 4.91 92.23 ± 1.58 95.97 ± 1.52
QUER
0.47 84.33 ± 2.04 0.45 ± 0.02 3.46 -4.2 0.48 ± 0.03 5.27 3.1 103.1 ± 0.03 96.02 ± 0.01 101.1 ± 0.03
5.30 93.24 ± 3.43 4.96 ± 0.05 1.06 -6.5 5.07 ± 0.23 4.50 -4.4 95.63 ± 0.23 93.72 ± 0.03 97.10 ± 0.29
60.00 87.61 ± 4.85 63.97 ± 1.32 2.06 6.6 58.63 ± 1.23 2.09 -2.3 97.72 ± 1.23 98.97 ± 1.45 92.36 ± 0.27
HP
3.13 85.55 ± 1.53 3.23 ± 0.21 6.46 3.3 3.34 ± 0.23 7.00 6.9 106.9 ± 0.23 103.4 ± 0.23 105.9 ± 0.28
13.69 93.65 ± 2.41 12.56 ± 0.29 2.30 -8.2 12.82 ± 0.26 2.05 -6.4 93.60 ± 0.26 97.76 ± 0.26 94.89 ± 0.29
60.00 86.70 ± 3.31 64.21 ± 1.65 2.57 7.0 64.45 ± 2.30 3.56 7.4 98.09 ± 1.57 99.33 ± 1.37 97.14 ± 0.22
TABLE VI - Concentrations of CA, p-CA, FA, QUER and HP in different rat tissues after oral administration of POE (n = 5)
Time 
(min)
Concentration (mg·g-1)
Liver Intestine Stomach Muscle Heart Lung Brain Kidney Spleen 
CA 10 - 1.18 ± 0.20 2.18 ± 0.23 0.290 ± 0.03 - - - - -
30 - 0.126 ± 0.04 0.613 ± 0.08 - - - - - -
60 - 0.628 ± 0.04 1.95 ± 0.20 - - - - - -
90 - 0.611 ± 0.02 1.64 ± 0.10 - - - - - -
150 - 0.202 ± 0.09 2.61 ± 0.10 - - - - - -
p-CA 10 0.0236 ± 0.003 0.367 ± 0.07 3.02 ± 0.10 0.0719 ± 0.03 0.0396 ± 0.003 0.0582 ± 0.003 - 0.0490 ± 0.001 0.0333 ± 0.007
30 0.00740 ± 0.0003 0.0236 ± 0.01 1.13 ± 0.03 0.0114 ± 0.003 0.0144 ± 0.003 0.0420 ± 0.003 - 0.0580 ± 0.03 0.0228 ± 0.001
60 0.00582 ± 0.0007 0.0351 ± 0.003 1.53 ± 0.03 - 0.0459 ± 0.007 0.0534 ± 0.02 - 0.0601 ± 0.007 0.0136 ± 0.03
90 0.0148 ± 0.003 0.0944 ± 0.03 1.99 ± 0.10 - 0.0364 ± 0.003 0.0490 ± 0.03 - 0.0396 ± 0.002 0.0142 ± 0.002
150 - 0.0320 ± 0.003 1.13 ± 0.04 0.0144 ± 0.003 0.0312 ± 0.003 0.0672 ± 0.001 - 0.0484 ± 0.02 0.0316 ± 0.0007
FA 10 0.178 ± 0.05 5.54 ± 0.40 32.7 ± 0.60 0.876 ± 0.30 0.297 ± 0.090 0.0592 ± 0.009 - 3.09 ± 0.42 0.314 ± 0.09
30 - 0.782 ± 0.02 11.5 ± 0.60 0.200 ± 0.04 0.286 ± 0.05 - -  2.00 ± 0.10 0.387 ± 0.10
60 - 2.87 ± 0.50 9.54 ± 0.40 0.0844 ± 0.009 0.250 ± 0.02 0.0148 ± 0.009 - 2.07 ± 0.40 0.268 ± 0.08
90 - 4.38 ± 0.80 16.5 ± 0.70 - - 0.0670 ± 0.008 - 0.0211 ± 0.009 0.584 ± 0.02
150 - 1.79 ± 0.07 10.0 ± 0.50 0.145 ± 0.09 - - 0.373 ± 0.09 0.822 ± 0.03 0.147 ± 0.02
QUER 10 0.0290 ± 0.01 0.146 ± 0.004 0.0279 ± 0.10 - - - - - -
30 0.0127 ± 0.001 - 0.213 ± 0.04 - - - - - -
60 0.0462 ± 0.004 - 0.772 ± 0.06 - - - - - -
90 - 0.580 ± 0.07 0.190 ± 0.04 - - - - - -
150 - 3.05 ± 0.04 0.253 ± 0.03 - - - - - -
HP 10 10.6 ± 2.0 9.59 ± 1.3 530.2 ± 4.00 - - - - - -
30 5.63 ± 1.0 - 182.7 ± 3.00 11.9 ± 0.23 - - - 6.00 ± 0.20 -
60 13.9 ± 0.67 - 140.8 ± 4.13 - - - - 4.11 ± 0.08 -
90 11.9 ± 0.33 - 291.2 ± 4.67 - - - - 16.4 ± 0.17 -
150 18.9 ± 1.0 10. 8 ± 2.7 383.2 ± 3.33 - - - - 12.5 ± 0.32 -
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cumulative ratios, indicating that extensive metabolism 
and excretion via other routes might occur, or a higher 
tissue distribution might occur.
CONCLUSIONS
A rapid, sensitive and specific UHPLC method 
with the internal standard was developed and validated 
for the determination of five components in POE. At 
the same time, the behavior of these five components 
of POE was also characterized in rat tissues after oral 
administration. Taken together, the study on tissue 
distributions and excretion of these five components of 
POE is of significance for its clinic applications in the 
future.
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FIGURE 3 - (A) Urinary cumulative ratios of the five analytes in 
rats (mean ± SD, n = 5) following oral administration of POE. 
(B) Fecal cumulative ratios of the five analytes in rats (mean ± 
SD, n = 5) following oral administration of POE.

